1 / 57

DIABETES Arshia Panahloo Consultant Diabetologist St. George's Hospital , London

DIABETES Arshia Panahloo Consultant Diabetologist St. George's Hospital , London. www.addison.ac.uk. Topics to be covered:. Diagnosis Classification Epidemiology and Pathogenesis Complications. Diagnosis. Diagnosis. Hyperglycaemia central to the diagnosis Diagnostic confusion

hector-bruce
Download Presentation

DIABETES Arshia Panahloo Consultant Diabetologist St. George's Hospital , London

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DIABETES Arshia Panahloo Consultant Diabetologist St. George's Hospital , London

  2. www.addison.ac.uk

  3. Topics to be covered: • Diagnosis • Classification • Epidemiology and Pathogenesis • Complications

  4. Diagnosis

  5. Diagnosis • Hyperglycaemia central to the diagnosis • Diagnostic confusion • 1985 WHO criteria,based on an oral glucose tolerance test • American Diabetes Association set their own criteria in 1997 • WHO revised in 1998

  6. WHO 1985 Diagnostic Criteria

  7. ADA 1997 Diagnostic Criteria

  8. Diagnosis In the presence of symptoms: (polyuria, polydipsia,weight loss) • Random plasma glucose  11.1 mmol/l OR • Fasting plasma glucose  7.0 mmol/l OR • 2 hour plasma glucose  11.1 mmol/l, 2hrs after a 75g oral glucose tolerance test

  9. Diagnosis In the absence of symptoms • Diagnosis should not be based on a single sample • Two samples on separate days, either: • fasting • random • 2 hour post load

  10. Diagnosis IGT and IFG • IGT (Impaired Glucose Tolerance) • Fasting plasma glucose < 7.0 mmol and 2 hour OGT value 7.8 -11.1 • IFG (Impaired Fasting Glycaemia) • fasting plasma glucose 6.1 - 7.0 mmol/l • IGT and IFG are not clinical entities in their own right but risk categories for cardiovascular disease (IGT) and/or future diabetes (IFG)

  11. Diagnosis • The diagnosis of diabetes has important legal and medical implications • Diagnosis should NOT be made on: • Glycosuria • Finger prick blood glucose • HbA1c • A venous plasma sample is needed in an accredited laboratory

  12. Classification

  13. Type 1 b cell destruction Type 2 insulin resistance +/- insulin deficiency due to b cell dysfunction Gestational diabetes Aetiological Classification WHO 1998

  14. Classification • Other specific types • genetic defects (b cell) • genetic defects (insulin) • exocrine pancreas • endocrinopathies • drug / chemical induced • infections • immune-mediated • other genetic syndromes

  15. Classification • Diabetes due to other endocrine disease: • Cushing’s syndrome • Acromegaly • Thyrotoxicosis • Phaeochromocytoma • Hyperaldosteronism • Glucagonoma

  16. Classification • Diabetes due drugs and chemicals: • Glucocorticoids • Diuretics • B-Blockers • B2-agonists • Phenytoin • Cyclosporin • Nicotinic acid

  17. Classification • Diabetes associated with genetic syndromes • DIDMOAD (Wolfram) syndrome • Myotonic dystrophy and other muscular disorders • Lipoatrophic diabetes • Type-1 glycogen storage disease • Cystic fibrosis

  18. Epidemiology and Pathogenesis of Type-1 Diabetes

  19. Type-1 Diabetes • Develops predominantly in children and young adults • Can occur in all age groups • Occurs in all continents • Marked geographical variation • Finland and Sardinia highest, 30-35 cases per 100,000 children aged up to 14 years • oriental populations lowest, <1 per 100,000

  20. Geographical variation • Variability is unexplained: • genetic factors • environmental factors • Incidence in childhood in increasing • ‘outbreaks’ suggest infectious agents • seasonal variation, highest in autumn and winter when viral infections more prevalent

  21. Presentation • Peak age of onset 11-13 years • 10% of diabetic patients over 60 years are insulin dependent • In UK the prevalence of type-1 DM is 1% (20% of total DM patients) • 20% of typical type-2 DM display evidence of autoimmunity

  22. Natural History of Type-1 DM • Commonest cause is autoimmune destruction of B-cells • Interaction between genetic factors and environment • Onset is abrupt, but B-cell antigens may be present for many years • Pre-diabetic state mild abnormalities of insulin secretion and glucose tolerance can be detected

  23. ‘Honeymoon period’ • After starting insulin, some patients need very small amounts • Last 2-12 months • Improvement in B-cell function once ‘glucose toxicity’ removed • True remission rare • Research into preserving B-cell function

  24. Genetic Factors (1) • Account for a third of the susceptibility to type-1 DM • 36% concordance for monozygotic twins • Over 20 regions of the human genome show some linkage with type-1 DM • Strongest linkage is with HLA genes within the MCH region on chrom. 6

  25. Genetic Factors (2) • HLA haplotypes DR3 and DR4 predispose to type-1 DM • linkage disequilibrium with true susceptibility loci • HLA class II antigens on the cell surface present foreign and self antigens to T-lymphocytes and initiate the auto- immune response

  26. Genetic Factors (3) • Strong linkage between HLA-DR and DQ regions • Polymorphisms of the DQB1 gene resulting in amino acid substitution in class II antigens may determine B-cell damage • Region of the insulin gene on chrom. 11 is linked to type-1 DM, insulin or pre-cursors can act as B-cell autoantigens

  27. Environmental Factors • Viruses • Dietary components • Stress • Drugs and toxins

  28. Viruses • Viruses can directly destroy B-cells or indirectly by an autoimmune response • Mumps • Occasionally precedes IDDM • autoimmune B-cell destruction • islet cell antibodies develop • can induce interleukin production and HLA hyperexpression in B-cells

  29. Viruses • Coxsackie B • IgM anti-coxsackie B antibodies in newly diagnosed type-1 DM • Antigen identified in islets post-mortem • Direct cytotoxic action on B-cells • Retroviruses • Rubella • CMV • Epstein-Barr

  30. Nutrients • ? Nitrosamines in diet • Breast feeding • short duration associated with increased risk of adult Type-1 diabetes in some studies • Antibodies to cow’s milk protein found in higher titres in children with recent onset type-1 diabetes

  31. Epidemiology and Pathogenesis of Type-2 Diabetes

  32. Type 1 Type 2 Incidence of type 2 diabetes rapidly increasing 3 million in the UK by 2010 3000 2500 2000 Diabetes prevalence (thousands) 1500 1000 500 0 2010 2000 1995 Amos AF et al. Diabet Med 1997;14(Suppl 5);S1–S85

  33. Geographical variation • Large variation • Highest in some native American tribes (Pima Indians) in Arizona (50%) and South Pacific Islands • Low prevalence in least developed rural communities • Prevalence is closely associated with BMI

  34. Type-2 Diabetes in the UK • Prevalence: • 1-2% for the white population • 11% for Indian • 9% for African-Caribbeans • Compared to white patients Indian patients have younger age of onset of type-2 diabetes and earlier protinuria and renal disease, and excess CHD.

  35. Type-2 Diabetes • Accounts for 85% of the diabetic population • Patients do not require insulin to remain alive, although 20% are treated with insulin to control blood glucose • Peak age of onset is 60 years, younger age of onset seen with MODY

  36. Type-2 Diabetes • Is characterized by variable combinations of insulin resistance and insulin deficiency • Insulin deficiency is less severe than type-1 diabetes and insulin levels remain high enough to prevent excess lipolysis and ketoacidosis • Patients are C-peptide positive

  37. Insulin Resistance Inability of insulin to produce its usual biological effects at circulating concentrations that are effective in normal subjects.

  38. Acquired causes of insulin resistance • 1) Obesity • truncal obesity (visceral fat) is related to insulin resistance • BMI >35 have 40 x risk of developing DM compared with those with BMI < 23 • visceral fat is especially susceptible to lipolysis and hence raised NEFA • truncal obesity is associated with increased proportion of white muscle fibres which are more insulin resistant than red fibres

  39. 2) Reduced physical activity • exercise increases : • insulin sensitive red fibres • fat oxidative enzymes • tissue (white adipose) sensitivity to catecholamines and enhancing lipolysis • hence exercise increases insulin sensitivity & increased utilisation of fat as fuel • 3) Malnutrition in foetal/early infant life • low birth wt. assoc with metabolic syndorme X in later life (obesity,insulin resistance & DM, hypertension, dyslipidaemia, atherosclerosis)

  40. Management of Type II Diabetes • Aims :- • Abolish symptoms and acute complications of hyperglycaemia • Reduce threat of chronic complications • Increase life expectancy • Restore quality of life

  41. Genetics of Type II Diabetes • High rate of concordance (60-100%) for the disease in identical twins • Familial aggregation • Different prevalence in ethnic groups • Polygenic trait with environmental factors • MODY (0.3% type-2) mutations in glucokinase gene • Mutations in mitochondrial DNA (rare)

  42. Complications

  43. Complications of Diabetes • Microvascular: • Nephropathy • Retinopathy • Neuropathy • Macrovascular • Coronary heart disease / Stroke /lipids • Peripheral vascular disease • Blood pressure

  44. Retinopathy • Type-1: • Rare less than 5 years of diabetes • With increasing prevalence the incidence rises to a peak at 15-20 years • Severe proliferative retinopathy also increases with diabetes duration, >20yrs • Type-2: • Can be present at diagnosis • Increased incidence of macular oedema

  45. Retinopathy • Risk Factors: • Poor glycaemic control • Genetic factors • Blood pressure • Smoking

More Related